ID   PTN6_HUMAN              Reviewed;         595 AA.
AC   P29350; A8K306; G3V0F8; Q969V8; Q9UK67;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   18-JUN-2025, entry version 257.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 6;
DE            EC=3.1.3.48 {ECO:0000269|PubMed:29925997, ECO:0000269|PubMed:38532423};
DE   AltName: Full=Hematopoietic cell protein-tyrosine phosphatase;
DE   AltName: Full=Protein-tyrosine phosphatase 1C;
DE            Short=PTP-1C;
DE   AltName: Full=Protein-tyrosine phosphatase SHP-1;
DE   AltName: Full=SH-PTP1;
GN   Name=PTPN6; Synonyms=HCP, PTP1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=1732748; DOI=10.1128/mcb.12.2.836-846.1992;
RA   Yi T., Cleveland J.L., Ihle J.N.;
RT   "Protein tyrosine phosphatase containing SH2 domains: characterization,
RT   preferential expression in hematopoietic cells, and localization to human
RT   chromosome 12p12-p13.";
RL   Mol. Cell. Biol. 12:836-846(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Mammary gland;
RX   PubMed=1652101; DOI=10.1038/352736a0;
RA   Shen S.H., Bastien L., Posner B.I., Chretien P.;
RT   "A protein-tyrosine phosphatase with sequence similarity to the SH2 domain
RT   of the protein-tyrosine kinases.";
RL   Nature 352:736-739(1991).
RN   [3]
RP   ERRATUM OF PUBMED:1652101, AND SEQUENCE REVISION.
RA   Shen S.H., Bastien L., Posner B.I., Chretien P.;
RL   Nature 353:868-868(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1736296; DOI=10.1073/pnas.89.3.1123;
RA   Plutzky J., Neel B.G., Rosenberg R.D.;
RT   "Isolation of a src homology 2-containing tyrosine phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1123-1127(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3).
RX   PubMed=7665165; DOI=10.1006/geno.1995.1020;
RA   Banville D., Stocco R., Shen S.H.;
RT   "Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate
RT   promoter usage and exon skipping generate multiple transcripts.";
RL   Genomics 27:165-173(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RX   PubMed=10497187; DOI=10.1074/jbc.274.40.28301;
RA   Jin Y.J., Yu C.L., Burakoff S.J.;
RT   "Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure
RT   and catalytic activity.";
RL   J. Biol. Chem. 274:28301-28307(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).
RA   Oka T., Ouchida M.;
RT   "Gene silencing of SHP-1 gene in leukemias/lymphomas by aberrant
RT   methylation.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PHOSPHORYLATION.
RX   PubMed=7781604; DOI=10.1002/j.1460-2075.1995.tb07249.x;
RA   Li R.Y., Gaits F., Ragab A., Ragab-Thomas J.M.F., Chap H.;
RT   "Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase
RT   is coupled to platelet thrombin receptor via a pertussis toxin-sensitive
RT   heterotrimeric G-protein.";
RL   EMBO J. 14:2519-2526(1995).
RN   [14]
RP   INTERACTION WITH LILRB1.
RX   PubMed=9285411; DOI=10.1016/s1074-7613(00)80529-4;
RA   Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., Hsu M.-L.;
RT   "A novel immunoglobulin superfamily receptor for cellular and viral MHC
RT   class I molecules.";
RL   Immunity 7:273-282(1997).
RN   [15]
RP   INTERACTION WITH LILRB4.
RX   PubMed=9151699; DOI=10.1084/jem.185.10.1743;
RA   Cella M., Doehring C., Samaridis J., Dessing M., Brockhaus M.,
RA   Lanzavecchia A., Colonna M.;
RT   "A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages,
RT   and dendritic cells involved in antigen processing.";
RL   J. Exp. Med. 185:1743-1751(1997).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9065461; DOI=10.1074/jbc.272.12.7927;
RA   Imani F., Rager K.J., Catipovic B., Marsh D.G.;
RT   "Interleukin-4 (IL-4) induces phosphatidylinositol 3-kinase (p85)
RT   dephosphorylation. Implications for the role of SHP-1 in the IL-4-induced
RT   signals in human B cells.";
RL   J. Biol. Chem. 272:7927-7931(1997).
RN   [17]
RP   INTERACTION WITH LILRB2.
RX   PubMed=9842885;
RX   DOI=10.1002/(sici)1521-4141(199811)28:11<3423::aid-immu3423>3.0.co;2-2;
RA   Fanger N.A., Cosman D., Peterson L., Braddy S.C., Maliszewski C.R.,
RA   Borges L.;
RT   "The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-
RT   mediated signaling in monocytes.";
RL   Eur. J. Immunol. 28:3423-3434(1998).
RN   [18]
RP   FUNCTION.
RX   PubMed=9733788; DOI=10.1074/jbc.273.38.24839;
RA   Keilhack H., Tenev T., Nyakatura E., Godovac-Zimmermann J., Nielsen L.,
RA   Seedorf K., Boehmer F.D.;
RT   "Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase
RT   SHP-1 to the epidermal growth factor receptor and attenuation of receptor
RT   signaling.";
RL   J. Biol. Chem. 273:24839-24846(1998).
RN   [19]
RP   INTERACTION WITH SIRPA.
RX   PubMed=9712903; DOI=10.1074/jbc.273.35.22719;
RA   Veillette A., Thibaudeau E., Latour S.;
RT   "High expression of inhibitory receptor SHPS-1 and its association with
RT   protein tyrosine phosphatase SHP-1 in macrophages.";
RL   J. Biol. Chem. 273:22719-22728(1998).
RN   [20]
RP   PHOSPHORYLATION AT TYR-564, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS
RP   OF TYR-564.
RX   PubMed=10574931; DOI=10.1074/jbc.274.49.34663;
RA   Yoshida K., Kharbanda S., Kufe D.;
RT   "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the
RT   apoptotic response to DNA damage.";
RL   J. Biol. Chem. 274:34663-34668(1999).
RN   [21]
RP   INTERACTION WITH FCRL2 AND FCRL3.
RX   PubMed=11162587; DOI=10.1006/bbrc.2000.4213;
RA   Xu M.-J., Zhao R., Zhao Z.J.;
RT   "Molecular cloning and characterization of SPAP1, an inhibitory receptor.";
RL   Biochem. Biophys. Res. Commun. 280:768-775(2001).
RN   [22]
RP   INTERACTION WITH CD84.
RX   PubMed=11414741; DOI=10.1006/clim.2001.5035;
RA   Lewis J., Eiben L.J., Nelson D.L., Cohen J.I., Nichols K.E., Ochs H.D.,
RA   Notarangelo L.D., Duckett C.S.;
RT   "Distinct interactions of the X-linked lymphoproliferative syndrome gene
RT   product SAP with cytoplasmic domains of members of the CD2 receptor
RT   family.";
RL   Clin. Immunol. 100:15-23(2001).
RN   [23]
RP   FUNCTION IN ROS1 DEPHOSPHORYLATION, AND INTERACTION WITH ROS1.
RX   PubMed=11266449; DOI=10.1083/jcb.152.2.325;
RA   Keilhack H., Mueller M., Boehmer S.A., Frank C., Weidner K.M.,
RA   Birchmeier W., Ligensa T., Berndt A., Kosmehl H., Guenther B., Mueller T.,
RA   Birchmeier C., Boehmer F.D.;
RT   "Negative regulation of Ros receptor tyrosine kinase signaling. An
RT   epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1.";
RL   J. Cell Biol. 152:325-334(2001).
RN   [24]
RP   FUNCTION, AND MUTAGENESIS OF ASP-419.
RX   PubMed=11907092; DOI=10.4049/jimmunol.168.7.3351;
RA   Bellon T., Kitzig F., Sayos J., Lopez-Botet M.;
RT   "Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of
RT   the Ig-like transcript 2 (CD85j) leukocyte receptor.";
RL   J. Immunol. 168:3351-3359(2002).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [26]
RP   INTERACTION WITH FCRL4.
RX   PubMed=14597715; DOI=10.1073/pnas.1935944100;
RA   Ehrhardt G.R.A., Davis R.S., Hsu J.T., Leu C.-M., Ehrhardt A., Cooper M.D.;
RT   "The inhibitory potential of Fc receptor homolog 4 on memory B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:13489-13494(2003).
RN   [27]
RP   INTERACTION WITH CD300LF.
RX   PubMed=15184070; DOI=10.1016/j.bbrc.2004.05.065;
RA   Sui L., Li N., Liu Q., Zhang W., Wan T., Wang B., Luo K., Sun H., Cao X.;
RT   "IgSF13, a novel human inhibitory receptor of the immunoglobulin
RT   superfamily, is preferentially expressed in dendritic cells and
RT   monocytes.";
RL   Biochem. Biophys. Res. Commun. 319:920-928(2004).
RN   [28]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [29]
RP   FUNCTION.
RX   PubMed=14739280; DOI=10.1074/jbc.m313127200;
RA   Marshall A.S.J., Willment J.A., Lin H.-H., Williams D.L., Gordon S.,
RA   Brown G.D.;
RT   "Identification and characterization of a novel human myeloid inhibitory C-
RT   type lectin-like receptor (MICL) that is predominantly expressed on
RT   granulocytes and monocytes.";
RL   J. Biol. Chem. 279:14792-14802(2004).
RN   [30]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [31]
RP   INTERACTION WITH LILRB4.
RX   PubMed=16493035; DOI=10.4049/jimmunol.176.5.2790;
RA   Kim-Schulze S., Scotto L., Vlad G., Piazza F., Lin H., Liu Z.,
RA   Cortesini R., Suciu-Foca N.;
RT   "Recombinant Ig-like transcript 3-Fc modulates T cell responses via
RT   induction of Th anergy and differentiation of CD8+ T suppressor cells.";
RL   J. Immunol. 176:2790-2798(2006).
RN   [32]
RP   INTERACTION WITH CLEC12B.
RX   PubMed=17562706; DOI=10.1074/jbc.m704250200;
RA   Hoffmann S.C., Schellack C., Textor S., Konold S., Schmitz D., Cerwenka A.,
RA   Pflanz S., Watzl C.;
RT   "Identification of CLEC12B, an inhibitory receptor on myeloid cells.";
RL   J. Biol. Chem. 282:22370-22375(2007).
RN   [33]
RP   INTERACTION WITH KIR2DL1.
RX   PubMed=18604210; DOI=10.1038/ni.1635;
RA   Yu M.-C., Su L.-L., Zou L., Liu Y., Wu N., Kong L., Zhuang Z.-H., Sun L.,
RA   Liu H.P., Hu J.-H., Li D., Strominger J.L., Zang J.-W., Pei G., Ge B.-X.;
RT   "An essential function for beta-arrestin 2 in the inhibitory signaling of
RT   natural killer cells.";
RL   Nat. Immunol. 9:898-907(2008).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PDPK1.
RX   PubMed=19591923; DOI=10.1016/j.cellsig.2009.06.010;
RA   Sephton C.F., Zhang D., Lehmann T.M., Pennington P.R., Scheid M.P.,
RA   Mousseau D.D.;
RT   "The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is
RT   dependent on its association with the protein tyrosine phosphatase SHP-1.";
RL   Cell. Signal. 21:1634-1644(2009).
RN   [35]
RP   INTERACTION WITH FCRL3.
RX   PubMed=19843936; DOI=10.4049/jimmunol.0901982;
RA   Kochi Y., Myouzen K., Yamada R., Suzuki A., Kurosaki T., Nakamura Y.,
RA   Yamamoto K.;
RT   "FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-
RT   cell receptor-mediated signaling.";
RL   J. Immunol. 183:5502-5510(2009).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-64, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [37]
RP   FUNCTION, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   SER-591.
RX   PubMed=20351292; DOI=10.1073/pnas.1002795107;
RA   Zhou X., Gallazzini M., Burg M.B., Ferraris J.D.;
RT   "Contribution of SHP-1 protein tyrosine phosphatase to osmotic regulation
RT   of the transcription factor TonEBP/OREBP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:7072-7077(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CDK2.
RX   PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019;
RA   Fiset A., Xu E., Bergeron S., Marette A., Pelletier G., Siminovitch K.A.,
RA   Olivier M., Beauchemin N., Faure R.L.;
RT   "Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and
RT   regulates insulin internalization.";
RL   Cell. Signal. 23:911-919(2011).
RN   [40]
RP   INTERACTION WITH FCRL6.
RX   PubMed=20933011; DOI=10.1016/j.imlet.2010.09.023;
RA   Kulemzin S.V., Zamoshnikova A.Y., Yurchenko M.Y., Vitak N.Y.,
RA   Najakshin A.M., Fayngerts S.A., Chikaev N.A., Reshetnikova E.S.,
RA   Kashirina N.M., Peclo M.M., Rutkevich P.N., Shevelev A.Y.,
RA   Yanushevskaya E.V., Baranov K.O., Mamonkin M., Vlasik T.N., Sidorenko S.P.,
RA   Taranin A.V., Mechetina L.V.;
RT   "FCRL6 receptor: expression and associated proteins.";
RL   Immunol. Lett. 134:174-182(2011).
RN   [41]
RP   INTERACTION WITH EGFR, AND FUNCTION.
RX   PubMed=21258366; DOI=10.1038/ncb2158;
RA   Hsu J.M., Chen C.T., Chou C.K., Kuo H.P., Li L.Y., Lin C.Y., Lee H.J.,
RA   Wang Y.N., Liu M., Liao H.W., Shi B., Lai C.C., Bedford M.T., Tsai C.H.,
RA   Hung M.C.;
RT   "Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation
RT   negatively modulates EGFR-mediated ERK activation.";
RL   Nat. Cell Biol. 13:174-181(2011).
RN   [42]
RP   INTERACTION WITH MPIG6B.
RX   PubMed=23112346; DOI=10.1126/scisignal.2002936;
RA   Mazharian A., Wang Y.J., Mori J., Bem D., Finney B., Heising S., Gissen P.,
RA   White J.G., Berndt M.C., Gardiner E.E., Nieswandt B., Douglas M.R.,
RA   Campbell R.D., Watson S.P., Senis Y.A.;
RT   "Mice lacking the ITIM-containing receptor G6b-B exhibit
RT   macrothrombocytopenia and aberrant platelet function.";
RL   Sci. Signal. 5:RA78-RA78(2012).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [45]
RP   FUNCTION, UBIQUITINATION AT LYS-308, MUTAGENESIS OF LYS-308, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=29925997; DOI=10.1038/s41590-018-0137-8;
RA   Aki D., Li H., Zhang W., Zheng M., Elly C., Lee J.H., Zou W., Liu Y.C.;
RT   "The E3 ligases Itch and WWP2 cooperate to limit TH2 differentiation by
RT   enhancing signaling through the TCR.";
RL   Nat. Immunol. 19:766-775(2018).
RN   [46]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH HIV-1 VIF (MICROBIAL
RP   INFECTION).
RX   PubMed=34811497; DOI=10.1038/s41423-021-00802-9;
RA   Wang Y., Qian G., Zhu L., Zhao Z., Liu Y., Han W., Zhang X., Zhang Y.,
RA   Xiong T., Zeng H., Yu X., Yu X., Zhang X., Xu J., Zou Q., Yan D.;
RT   "HIV-1 Vif suppresses antiviral immunity by targeting STING.";
RL   Cell. Mol. Immunol. 19:108-121(2022).
RN   [47]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH POLR2C AND POLR2J, AND
RP   MUTAGENESIS OF CYS-453.
RX   PubMed=37595871; DOI=10.1016/j.jbc.2023.105164;
RA   Kumar A., Schwab M., Laborit Labrada B., Silveira M.A.D., Goudreault M.,
RA   Fournier E., Bellmann K., Beauchemin N., Gingras A.C., Bilodeau S.,
RA   Laplante M., Marette A.;
RT   "SHP-1 phosphatase acts as a coactivator of PCK1 transcription to control
RT   gluconeogenesis.";
RL   J. Biol. Chem. 299:105164-105164(2023).
RN   [48]
RP   FUNCTION.
RX   PubMed=37932456; DOI=10.1038/s41590-023-01658-z;
RA   Velasco Cardenas R.M., Brandl S.M., Melendez A.V., Schlaak A.E.,
RA   Buschky A., Peters T., Beier F., Serrels B., Taromi S., Raute K., Hauri S.,
RA   Gstaiger M., Lassmann S., Huppa J.B., Boerries M., Andrieux G., Bengsch B.,
RA   Schamel W.W., Minguet S.;
RT   "Harnessing CD3 diversity to optimize CAR T cells.";
RL   Nat. Immunol. 24:2135-2149(2023).
RN   [49]
RP   PHOSPHORYLATION AT THR-394, UBIQUITINATION, AND FUNCTION.
RX   PubMed=38166031; DOI=10.1126/scisignal.adg4422;
RA   Poirier A., Ormonde J.V.S., Aubry I., Abidin B.M., Feng C.H.,
RA   Martinez-Cordova Z., Hincapie A.M., Wu C., Perez-Quintero L.A., Wang C.L.,
RA   Gingras A.C., Madrenas J., Tremblay M.L.;
RT   "The induction of SHP-1 degradation by TAOK3 ensures the responsiveness of
RT   T cells to TCR stimulation.";
RL   Sci. Signal. 17:eadg4422-eadg4422(2024).
RN   [50]
RP   FUNCTION, INTERACTION WITH TNFRSF10A, AND CATALYTIC ACTIVITY.
RX   PubMed=38532423; DOI=10.1186/s12929-024-01023-8;
RA   Chyuan I.T., Liao H.J., Tan T.H., Chuang H.C., Chu Y.C., Pan M.H., Wu C.S.,
RA   Chu C.L., Sheu B.C., Hsu P.N.;
RT   "Association of TRAIL receptor with phosphatase SHP-1 enables repressing T
RT   cell receptor signaling and T cell activation through inactivating Lck.";
RL   J. Biomed. Sci. 31:33-33(2024).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 248-399.
RX   PubMed=9774441; DOI=10.1074/jbc.273.43.28199;
RA   Yang J., Liang X., Niu T., Meng W., Zhao Z., Zhou G.W.;
RT   "Crystal structure of the catalytic domain of protein-tyrosine phosphatase
RT   SHP-1.";
RL   J. Biol. Chem. 273:28199-28207(1998).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-532, AND DOMAIN SH2.
RX   PubMed=12482860; DOI=10.1074/jbc.m210430200;
RA   Yang J., Liu L., He D., Song X., Liang X., Zhao Z.J., Zhou G.W.;
RT   "Crystal structure of human protein-tyrosine phosphatase SHP-1.";
RL   J. Biol. Chem. 278:6516-6520(2003).
RN   [53]
RP   STRUCTURE BY NMR OF 110-214.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the SH2 domain of human protein-tyrosine
RT   phosphatase SHP-1.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS), AND DOMAIN SH2.
RX   PubMed=21465528; DOI=10.1002/jcb.23125;
RA   Wang W., Liu L., Song X., Mo Y., Komma C., Bellamy H.D., Zhao Z.J.,
RA   Zhou G.W.;
RT   "Crystal structure of human protein tyrosine phosphatase SHP-1 in the open
RT   conformation.";
RL   J. Cell. Biochem. 112:2062-2071(2011).
CC   -!- FUNCTION: Tyrosine phosphatase enzyme that plays important roles in
CC       controlling immune signaling pathways and fundamental physiological
CC       processes such as hematopoiesis (PubMed:14739280, PubMed:29925997).
CC       Dephosphorylates and negatively regulate several receptor tyrosine
CC       kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their
CC       signaling activities (PubMed:21258366, PubMed:9733788). When recruited
CC       to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing
CC       receptors such as immunoglobulin-like transcript 2/LILRB1, programmed
CC       cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors
CC       involved in immune regulation, initiates their dephosphorylation and
CC       subsequently inhibits downstream signaling events (PubMed:11907092,
CC       PubMed:14739280, PubMed:37932456, PubMed:38166031). Modulates the
CC       signaling of several cytokine receptors including IL-4 receptor
CC       (PubMed:9065461). Additionally, targets multiple cytoplasmic signaling
CC       molecules including STING1, LCK or STAT1 among others involved in
CC       diverse cellular processes including modulation of T-cell activation or
CC       cGAS-STING signaling (PubMed:34811497, PubMed:38532423). Within the
CC       nucleus, negatively regulates the activity of some transcription
CC       factors such as NFAT5 via direct dephosphorylation. Also acts as a key
CC       transcriptional regulator of hepatic gluconeogenesis by controlling
CC       recruitment of RNA polymerase II to the PCK1 promoter together with
CC       STAT5A (PubMed:37595871). {ECO:0000269|PubMed:10574931,
CC       ECO:0000269|PubMed:11266449, ECO:0000269|PubMed:11907092,
CC       ECO:0000269|PubMed:14739280, ECO:0000269|PubMed:21258366,
CC       ECO:0000269|PubMed:29925997, ECO:0000269|PubMed:34811497,
CC       ECO:0000269|PubMed:37595871, ECO:0000269|PubMed:37932456,
CC       ECO:0000269|PubMed:38166031, ECO:0000269|PubMed:38532423,
CC       ECO:0000269|PubMed:9065461, ECO:0000269|PubMed:9733788}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044, ECO:0000269|PubMed:29925997,
CC         ECO:0000269|PubMed:38532423};
CC   -!- SUBUNIT: Monomer. Interacts with MTUS1 (By similarity). Interacts with
CC       MILR1 (tyrosine-phosphorylated) (By similarity). Interacts with KIT (By
CC       similarity). Interacts with SIRPA/PTPNS1 (PubMed:9712903). Interacts
CC       with LILRB1 and LILRB2 (PubMed:9285411, PubMed:9842885). Interacts with
CC       LILRB4 (PubMed:16493035, PubMed:9151699). Interacts with FCRL2 and
CC       FCRL4 (PubMed:11162587, PubMed:14597715). Interacts with FCRL3 and
CC       FCRL6 (tyrosine phosphorylated form) (PubMed:11162587, PubMed:19843936,
CC       PubMed:20933011). Interacts with CD84 (PubMed:11414741). Interacts with
CC       CD300LF (PubMed:15184070). Interacts with CDK2 (PubMed:21262353).
CC       Interacts with KIR2DL1; the interaction is enhanced by ARRB2
CC       (PubMed:18604210). Interacts (via SH2 1 domain) with ROS1; the
CC       interaction is direct and promotes ROS1 dephosphorylation
CC       (PubMed:11266449). Interacts with EGFR; inhibits EGFR-dependent
CC       activation of MAPK/ERK (PubMed:21258366). Interacts with the tyrosine
CC       phosphorylated form of PDPK1 (PubMed:19591923). Interacts with CEACAM1
CC       (via cytoplasmic domain); this interaction depends on the monomer/dimer
CC       equilibrium and is phosphorylation-dependent (By similarity). Interacts
CC       with MPIG6B (via ITIM motif) (PubMed:23112346). Interacts with KLRI1
CC       and KLRI2 (By similarity). Interacts with moesin/MSN. Interacts with
CC       CLEC12B (via ITIM motif). Interacts with polymerase II components
CC       POLR2C and POLR2J; these interactions recruit RNA polymerase II to the
CC       PCK1 promoter (PubMed:37595871). Interacts with TNFRSF10A; this
CC       interaction enables the inhibition of T-cell receptor signaling via LCK
CC       (PubMed:38532423). {ECO:0000250|UniProtKB:P29351,
CC       ECO:0000250|UniProtKB:P81718, ECO:0000269|PubMed:11162587,
CC       ECO:0000269|PubMed:11266449, ECO:0000269|PubMed:11414741,
CC       ECO:0000269|PubMed:14597715, ECO:0000269|PubMed:15184070,
CC       ECO:0000269|PubMed:16493035, ECO:0000269|PubMed:17562706,
CC       ECO:0000269|PubMed:18604210, ECO:0000269|PubMed:19591923,
CC       ECO:0000269|PubMed:19843936, ECO:0000269|PubMed:20933011,
CC       ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:21262353,
CC       ECO:0000269|PubMed:23112346, ECO:0000269|PubMed:37595871,
CC       ECO:0000269|PubMed:38532423, ECO:0000269|PubMed:9151699,
CC       ECO:0000269|PubMed:9285411, ECO:0000269|PubMed:9712903,
CC       ECO:0000269|PubMed:9842885}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Vif; this
CC       interaction promotes the suppression of cytokine production.
CC       {ECO:0000269|PubMed:34811497}.
CC   -!- INTERACTION:
CC       P29350; Q14790: CASP8; NbExp=3; IntAct=EBI-78260, EBI-78060;
CC       P29350; P20273: CD22; NbExp=4; IntAct=EBI-78260, EBI-78277;
CC       P29350; Q9BZW8: CD244; NbExp=2; IntAct=EBI-78260, EBI-1580565;
CC       P29350; P20138: CD33; NbExp=10; IntAct=EBI-78260, EBI-3906571;
CC       P29350; P11049: CD37; NbExp=4; IntAct=EBI-78260, EBI-6139068;
CC       P29350; P19235: EPOR; NbExp=11; IntAct=EBI-78260, EBI-617321;
CC       P29350; P31994: FCGR2B; NbExp=3; IntAct=EBI-78260, EBI-724784;
CC       P29350; Q13643: FHL3; NbExp=3; IntAct=EBI-78260, EBI-741101;
CC       P29350; P62993: GRB2; NbExp=3; IntAct=EBI-78260, EBI-401755;
CC       P29350; P08069: IGF1R; NbExp=3; IntAct=EBI-78260, EBI-475981;
CC       P29350; P35968: KDR; NbExp=2; IntAct=EBI-78260, EBI-1005487;
CC       P29350; P43626: KIR2DL1; NbExp=4; IntAct=EBI-78260, EBI-8684277;
CC       P29350; P43628: KIR2DL3; NbExp=13; IntAct=EBI-78260, EBI-8632435;
CC       P29350; Q6GTX8: LAIR1; NbExp=5; IntAct=EBI-78260, EBI-965864;
CC       P29350; P06239: LCK; NbExp=5; IntAct=EBI-78260, EBI-1348;
CC       P29350; Q8NHL6: LILRB1; NbExp=4; IntAct=EBI-78260, EBI-2805262;
CC       P29350; Q8N423: LILRB2; NbExp=3; IntAct=EBI-78260, EBI-2816428;
CC       P29350; O75022: LILRB3; NbExp=4; IntAct=EBI-78260, EBI-2830524;
CC       P29350; Q8NHJ6: LILRB4; NbExp=4; IntAct=EBI-78260, EBI-2805248;
CC       P29350; O94916-1: NFAT5; NbExp=4; IntAct=EBI-78260, EBI-15828651;
CC       P29350; P16284: PECAM1; NbExp=4; IntAct=EBI-78260, EBI-716404;
CC       P29350; Q9UKJ1: PILRA; NbExp=5; IntAct=EBI-78260, EBI-965833;
CC       P29350; Q05209: PTPN12; NbExp=3; IntAct=EBI-78260, EBI-2266035;
CC       P29350; P08922: ROS1; NbExp=2; IntAct=EBI-78260, EBI-7371065;
CC       P29350; Q8N1K5: THEMIS; NbExp=4; IntAct=EBI-78260, EBI-2873538;
CC       P29350; O35274: Ppp1r9b; Xeno; NbExp=2; IntAct=EBI-78260, EBI-80022;
CC       P29350; B7UM99: tir; Xeno; NbExp=4; IntAct=EBI-78260, EBI-2504426;
CC       P29350; Q7DB77: tir; Xeno; NbExp=2; IntAct=EBI-78260, EBI-6480811;
CC       P29350-3; Q05397: PTK2; NbExp=3; IntAct=EBI-7399369, EBI-702142;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:34811497,
CC       ECO:0000269|PubMed:9065461}. Nucleus {ECO:0000269|PubMed:37595871}.
CC       Note=In neurons, translocates into the nucleus after treatment with
CC       angiotensin II (By similarity). Shuttles between the cytoplasm and
CC       nucleus via its association with PDPK1. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P29350-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29350-3; Sequence=VSP_007775;
CC       Name=3; Synonyms=Short;
CC         IsoId=P29350-2; Sequence=VSP_005129, VSP_005130;
CC       Name=4; Synonyms=70-kDa, SHP-1L;
CC         IsoId=P29350-4; Sequence=VSP_044447;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in hematopoietic cells.
CC       Isoform 2 is expressed in non-hematopoietic cells.
CC       {ECO:0000269|PubMed:1732748}.
CC   -!- DOMAIN: The N-terminal SH2 domain functions as an auto-inhibitory
CC       domain, blocking the catalytic domain in the ligand-free close
CC       conformation. {ECO:0000269|PubMed:12482860,
CC       ECO:0000269|PubMed:21465528}.
CC   -!- PTM: Phosphorylated on tyrosine residues. Binding of KITLG/SCF to KIT
CC       increases tyrosine phosphorylation (By similarity). Phosphorylation at
CC       Tyr-564 by LYN enhances phosphatase activity. Phosphorylation at Thr-
CC       394 by TAOK3 leads to polyubiquitination and subsequent proteasomal
CC       degradation (PubMed:38166031). {ECO:0000250|UniProtKB:P29351,
CC       ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:38166031,
CC       ECO:0000269|PubMed:38532423, ECO:0000269|PubMed:7781604}.
CC   -!- PTM: Ubiquitinated after phosphorylation by TAOK3 (PubMed:38166031).
CC       Ubiquitinated by a cooperation between ITCH and WWP2 via 'Lys-27'-
CC       mediated polyubiquitin chains resulting in the reduction of its
CC       association with LCK (PubMed:29925997). {ECO:0000269|PubMed:29925997,
CC       ECO:0000269|PubMed:38166031}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family. Non-
CC       receptor class 2 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41920/PTPN6";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M74903; AAA35963.1; -; mRNA.
DR   EMBL; X62055; CAA43982.1; -; mRNA.
DR   EMBL; M77273; AAA36610.1; -; mRNA.
DR   EMBL; U15528; AAA82880.1; -; Genomic_DNA.
DR   EMBL; U15536; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15535; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15534; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15533; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15532; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15531; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15530; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15529; AAA82880.1; JOINED; Genomic_DNA.
DR   EMBL; U15528; AAA82879.1; -; Genomic_DNA.
DR   EMBL; U15537; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15535; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15534; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15533; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15532; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15531; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15530; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U15529; AAA82879.1; JOINED; Genomic_DNA.
DR   EMBL; U47924; AAB51322.1; -; Genomic_DNA.
DR   EMBL; U47924; AAB51323.1; -; Genomic_DNA.
DR   EMBL; AF178946; AAD53317.1; -; mRNA.
DR   EMBL; AB079851; BAC81774.1; -; Genomic_DNA.
DR   EMBL; AB079851; BAC81775.1; -; Genomic_DNA.
DR   EMBL; AK290421; BAF83110.1; -; mRNA.
DR   EMBL; CH471116; EAW88703.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88704.1; -; Genomic_DNA.
DR   EMBL; BC002523; AAH02523.1; -; mRNA.
DR   EMBL; BC007667; AAH07667.1; -; mRNA.
DR   CCDS; CCDS41744.1; -. [P29350-3]
DR   CCDS; CCDS44820.1; -. [P29350-1]
DR   CCDS; CCDS44821.1; -. [P29350-4]
DR   PIR; B42031; S20825.
DR   RefSeq; NP_002822.2; NM_002831.5. [P29350-1]
DR   RefSeq; NP_536858.1; NM_080548.5. [P29350-3]
DR   RefSeq; NP_536859.1; NM_080549.4. [P29350-4]
DR   RefSeq; XP_011519290.1; XM_011520988.2. [P29350-3]
DR   RefSeq; XP_024304874.1; XM_024449106.1. [P29350-1]
DR   RefSeq; XP_054228689.1; XM_054372714.1. [P29350-3]
DR   RefSeq; XP_054228690.1; XM_054372715.1. [P29350-1]
DR   PDB; 1FPR; X-ray; 2.50 A; A=243-526.
DR   PDB; 1GWZ; X-ray; 2.50 A; A=243-541.
DR   PDB; 1X6C; NMR; -; A=110-214.
DR   PDB; 2B3O; X-ray; 2.80 A; A=1-532.
DR   PDB; 2RMX; NMR; -; A=110-214.
DR   PDB; 2YU7; NMR; -; A=110-214.
DR   PDB; 3PS5; X-ray; 3.10 A; A=1-595.
DR   PDB; 4GRY; X-ray; 1.70 A; A=243-528.
DR   PDB; 4GRZ; X-ray; 1.37 A; A=243-528.
DR   PDB; 4GS0; X-ray; 1.80 A; A/B=243-528.
DR   PDB; 4HJP; X-ray; 1.40 A; A=243-528.
DR   PDB; 4HJQ; X-ray; 1.80 A; A/B=243-528.
DR   PDB; 6SM5; X-ray; 2.75 A; A=100-214.
DR   PDB; 8YHI; X-ray; 1.75 A; A=243-528.
DR   PDBsum; 1FPR; -.
DR   PDBsum; 1GWZ; -.
DR   PDBsum; 1X6C; -.
DR   PDBsum; 2B3O; -.
DR   PDBsum; 2RMX; -.
DR   PDBsum; 2YU7; -.
DR   PDBsum; 3PS5; -.
DR   PDBsum; 4GRY; -.
DR   PDBsum; 4GRZ; -.
DR   PDBsum; 4GS0; -.
DR   PDBsum; 4HJP; -.
DR   PDBsum; 4HJQ; -.
DR   PDBsum; 6SM5; -.
DR   PDBsum; 8YHI; -.
DR   AlphaFoldDB; P29350; -.
DR   SMR; P29350; -.
DR   BioGRID; 111742; 235.
DR   CORUM; P29350; -.
DR   DIP; DIP-31002N; -.
DR   FunCoup; P29350; 1765.
DR   IntAct; P29350; 126.
DR   MINT; P29350; -.
DR   STRING; 9606.ENSP00000391592; -.
DR   BindingDB; P29350; -.
DR   ChEMBL; CHEMBL3166; -.
DR   DrugBank; DB01133; Tiludronic acid.
DR   DrugCentral; P29350; -.
DR   MoonDB; P29350; Predicted.
DR   DEPOD; PTPN6; -.
DR   GlyCosmos; P29350; 2 sites, 2 glycans.
DR   GlyGen; P29350; 3 sites, 2 O-linked glycans (3 sites).
DR   iPTMnet; P29350; -.
DR   PhosphoSitePlus; P29350; -.
DR   BioMuta; PTPN6; -.
DR   DMDM; 131469; -.
DR   OGP; P29350; -.
DR   jPOST; P29350; -.
DR   MassIVE; P29350; -.
DR   PaxDb; 9606-ENSP00000391592; -.
DR   PeptideAtlas; P29350; -.
DR   ProteomicsDB; 32184; -.
DR   ProteomicsDB; 54543; -. [P29350-1]
DR   ProteomicsDB; 54544; -. [P29350-2]
DR   ProteomicsDB; 54545; -. [P29350-3]
DR   Pumba; P29350; -.
DR   Antibodypedia; 728; 1032 antibodies from 48 providers.
DR   CPTC; P29350; 3 antibodies.
DR   DNASU; 5777; -.
DR   Ensembl; ENST00000318974.14; ENSP00000326010.9; ENSG00000111679.17. [P29350-1]
DR   Ensembl; ENST00000399448.5; ENSP00000382376.1; ENSG00000111679.17. [P29350-3]
DR   Ensembl; ENST00000456013.5; ENSP00000391592.1; ENSG00000111679.17. [P29350-4]
DR   GeneID; 5777; -.
DR   KEGG; hsa:5777; -.
DR   MANE-Select; ENST00000318974.14; ENSP00000326010.9; NM_002831.6; NP_002822.2.
DR   UCSC; uc001qsb.3; human. [P29350-1]
DR   AGR; HGNC:9658; -.
DR   CTD; 5777; -.
DR   DisGeNET; 5777; -.
DR   GeneCards; PTPN6; -.
DR   HGNC; HGNC:9658; PTPN6.
DR   HPA; ENSG00000111679; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; PTPN6; -.
DR   MIM; 176883; gene.
DR   OpenTargets; ENSG00000111679; -.
DR   Orphanet; 538869; Bullous pyoderma gangrenosum.
DR   Orphanet; 538863; Classic pyoderma gangrenosum.
DR   Orphanet; 538866; Pustular pyoderma gangrenosum.
DR   Orphanet; 3243; Sweet syndrome.
DR   Orphanet; 538872; Vegetative pyoderma gangrenosum.
DR   VEuPathDB; HostDB:ENSG00000111679; -.
DR   eggNOG; KOG0790; Eukaryota.
DR   GeneTree; ENSGT00940000159480; -.
DR   InParanoid; P29350; -.
DR   OMA; VKIMCEN; -.
DR   OrthoDB; 8815311at2759; -.
DR   PAN-GO; P29350; 7 GO annotations based on evolutionary models.
DR   PhylomeDB; P29350; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; P29350; -.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-201556; Signaling by ALK.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-389948; Co-inhibition by PD-1.
DR   Reactome; R-HSA-391160; Signal regulatory protein family interactions.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-HSA-5690714; CD22 mediated BCR regulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-9008059; Interleukin-37 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA/IFNB signaling.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   Reactome; R-HSA-9927353; Co-inhibition by BTLA.
DR   SignaLink; P29350; -.
DR   SIGNOR; P29350; -.
DR   BioGRID-ORCS; 5777; 24 hits in 1178 CRISPR screens.
DR   ChiTaRS; PTPN6; human.
DR   EvolutionaryTrace; P29350; -.
DR   GeneWiki; PTPN6; -.
DR   GenomeRNAi; 5777; -.
DR   Pharos; P29350; Tchem.
DR   PRO; PR:P29350; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P29350; protein.
DR   Bgee; ENSG00000111679; Expressed in granulocyte and 192 other cell types or tissues.
DR   ExpressionAtlas; P29350; baseline and differential.
DR   GO; GO:0042105; C:alpha-beta T cell receptor complex; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProt.
DR   GO; GO:0032991; C:protein-containing complex; IMP:UniProtKB.
DR   GO; GO:0035580; C:specific granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IEA:Ensembl.
DR   GO; GO:0004726; F:non-membrane spanning protein tyrosine phosphatase activity; IBA:GO_Central.
DR   GO; GO:0140031; F:phosphorylation-dependent protein binding; IPI:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProt.
DR   GO; GO:0042169; F:SH2 domain binding; IEA:Ensembl.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:Ensembl.
DR   GO; GO:0005001; F:transmembrane receptor protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0160162; P:CD27 signaling pathway; IDA:UniProt.
DR   GO; GO:0030154; P:cell differentiation; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1905867; P:epididymis development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; IBA:GO_Central.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProt.
DR   GO; GO:0050859; P:negative regulation of B cell receptor signaling pathway; IDA:UniProt.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; NAS:UniProtKB.
DR   GO; GO:0002924; P:negative regulation of humoral immune response mediated by circulating immunoglobulin; IEA:Ensembl.
DR   GO; GO:0106015; P:negative regulation of inflammatory response to wounding; IDA:UniProt.
DR   GO; GO:0045824; P:negative regulation of innate immune response; IDA:UniProt.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; ISS:ARUK-UCL.
DR   GO; GO:0031665; P:negative regulation of lipopolysaccharide-mediated signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0033007; P:negative regulation of mast cell activation involved in immune response; IEA:Ensembl.
DR   GO; GO:1902564; P:negative regulation of neutrophil activation; IDA:UniProt.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; ISS:ARUK-UCL.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IEA:Ensembl.
DR   GO; GO:0030220; P:platelet formation; IEA:Ensembl.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:BHF-UCL.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0045577; P:regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IMP:BHF-UCL.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042110; P:T cell activation; IDA:UniProt.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0042098; P:T cell proliferation; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   CDD; cd14606; PTPc-N6; 1.
DR   CDD; cd09931; SH2_C-SH2_SHP_like; 1.
DR   CDD; cd10340; SH2_N-SH2_SHP_like; 1.
DR   FunFam; 3.30.505.10:FF:000012; Tyrosine-protein phosphatase non-receptor type; 1.
DR   FunFam; 3.30.505.10:FF:000018; Tyrosine-protein phosphatase non-receptor type; 1.
DR   FunFam; 3.90.190.10:FF:000018; Tyrosine-protein phosphatase non-receptor type; 1.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 2.
DR   InterPro; IPR052123; Non-rcpt_Tyr_Phosphatase.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTP_cat.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   InterPro; IPR012152; Tyr_Pase_non-rcpt_typ-6/11.
DR   PANTHER; PTHR46257; TYROSINE-PROTEIN PHOSPHATASE CORKSCREW; 1.
DR   PANTHER; PTHR46257:SF4; TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE 6; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000929; Tyr-Ptase_nr_6; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SMART; SM00252; SH2; 2.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1.
DR   SUPFAM; SSF55550; SH2 domain; 2.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
DR   neXtProt; NX_P29350; -.
DR   PharmGKB; PA34002; -.
DR   TreeFam; TF351632; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Hydrolase; Isopeptide bond;
KW   Nucleus; Phosphoprotein; Protein phosphatase; Proteomics identification;
KW   Reference proteome; Repeat; SH2 domain; Ubl conjugation.
FT   CHAIN           1..595
FT                   /note="Tyrosine-protein phosphatase non-receptor type 6"
FT                   /id="PRO_0000094758"
FT   DOMAIN          4..100
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          110..213
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          244..515
FT                   /note="Tyrosine-protein phosphatase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   REGION          535..595
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        558..589
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        453
FT                   /note="Phosphocysteine intermediate"
FT   BINDING         419
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         453..459
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         500
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P81718"
FT   MOD_RES         57
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P29351"
FT   MOD_RES         64
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         377
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P29351"
FT   MOD_RES         394
FT                   /note="Phosphothreonine; by TAOK3"
FT                   /evidence="ECO:0000269|PubMed:38166031"
FT   MOD_RES         536
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P29351"
FT   MOD_RES         564
FT                   /note="Phosphotyrosine; by LYN"
FT                   /evidence="ECO:0000269|PubMed:10574931"
FT   CROSSLNK        308
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:29925997"
FT   VAR_SEQ         1..39
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1652101"
FT                   /id="VSP_005129"
FT   VAR_SEQ         1..3
FT                   /note="MVR -> MLSRG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_007775"
FT   VAR_SEQ         40..44
FT                   /note="SLSVR -> MLSRG (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:1652101"
FT                   /id="VSP_005130"
FT   VAR_SEQ         559..595
FT                   /note="HKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK -> SLESSAGTVAA
FT                   SPVRRGGQRGLPVPGPPVLSPDLHQLPVLAPLHPAADTRRMCMRTCTLRTRGRRK (in
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10497187"
FT                   /id="VSP_044447"
FT   MUTAGEN         308
FT                   /note="K->R: Almost complete loss of ubiquitination by ITCH
FT                   and WWP2."
FT                   /evidence="ECO:0000269|PubMed:29925997"
FT   MUTAGEN         419
FT                   /note="D->A: No loss in substrate binding but impaired
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11907092"
FT   MUTAGEN         453
FT                   /note="C->S: Stabilizes the association between phosphatase
FT                   and substrates."
FT                   /evidence="ECO:0000269|PubMed:37595871"
FT   MUTAGEN         564
FT                   /note="Y->F: Complete loss of phosphorylation by LYN."
FT                   /evidence="ECO:0000269|PubMed:10574931"
FT   CONFLICT        6
FT                   /note="H -> L (in Ref. 5; AAA82880)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        86
FT                   /note="L -> V (in Ref. 4; AAA36610 and 7; AAD53317)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        146
FT                   /note="V -> E (in Ref. 5; AAA82880/AAA82879)"
FT                   /evidence="ECO:0000305"
FT   HELIX           11..21
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          26..31
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          33..45
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          48..55
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          57..59
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          61..63
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          68..70
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   HELIX           72..80
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   HELIX           105..107
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          111..114
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   HELIX           117..126
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          132..137
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          139..141
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          145..157
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          162..172
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          175..177
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          184..186
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   HELIX           187..197
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          199..202
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   STRAND          205..207
FT                   /evidence="ECO:0007829|PDB:6SM5"
FT   HELIX           221..223
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          236..238
FT                   /evidence="ECO:0007829|PDB:3PS5"
FT   HELIX           244..256
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   TURN            257..259
FT                   /evidence="ECO:0007829|PDB:4HJP"
FT   HELIX           263..266
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           268..273
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          275..278
FT                   /evidence="ECO:0007829|PDB:1GWZ"
FT   TURN            283..285
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          286..288
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          290..292
FT                   /evidence="ECO:0007829|PDB:4GS0"
FT   STRAND          294..296
FT                   /evidence="ECO:0007829|PDB:3PS5"
FT   TURN            297..300
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          301..307
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          309..312
FT                   /evidence="ECO:0007829|PDB:1GWZ"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:1FPR"
FT   STRAND          321..324
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           329..331
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           332..341
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          346..349
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          353..355
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          356..358
FT                   /evidence="ECO:0007829|PDB:1FPR"
FT   STRAND          371..374
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          377..386
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          388..399
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           400..402
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:1FPR"
FT   STRAND          407..414
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          419..421
FT                   /evidence="ECO:0007829|PDB:2B3O"
FT   STRAND          424..426
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           427..442
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          443..445
FT                   /evidence="ECO:0007829|PDB:4HJQ"
FT   STRAND          449..452
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   STRAND          454..457
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           458..476
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           484..492
FT                   /evidence="ECO:0007829|PDB:4GRZ"
FT   HELIX           502..523
FT                   /evidence="ECO:0007829|PDB:4GRZ"
SQ   SEQUENCE   595 AA;  67561 MW;  4D7736C21D3542D2 CRC64;
     MVRWFHRDLS GLDAETLLKG RGVHGSFLAR PSRKNQGDFS LSVRVGDQVT HIRIQNSGDF
     YDLYGGEKFA TLTELVEYYT QQQGVLQDRD GTIIHLKYPL NCSDPTSERW YHGHMSGGQA
     ETLLQAKGEP WTFLVRESLS QPGDFVLSVL SDQPKAGPGS PLRVTHIKVM CEGGRYTVGG
     LETFDSLTDL VEHFKKTGIE EASGAFVYLR QPYYATRVNA ADIENRVLEL NKKQESEDTA
     KAGFWEEFES LQKQEVKNLH QRLEGQRPEN KGKNRYKNIL PFDHSRVILQ GRDSNIPGSD
     YINANYIKNQ LLGPDENAKT YIASQGCLEA TVNDFWQMAW QENSRVIVMT TREVEKGRNK
     CVPYWPEVGM QRAYGPYSVT NCGEHDTTEY KLRTLQVSPL DNGDLIREIW HYQYLSWPDH
     GVPSEPGGVL SFLDQINQRQ ESLPHAGPII VHCSAGIGRT GTIIVIDMLM ENISTKGLDC
     DIDIQKTIQM VRAQRSGMVQ TEAQYKFIYV AIAQFIETTK KKLEVLQSQK GQESEYGNIT
     YPPAMKNAHA KASRTSSKHK EDVYENLHTK NKREEKVKKQ RSADKEKSKG SLKRK
//
